abstract: BACKGROUND: For the majority of @entity0 with @entity5 ( @entity5 ), joint replacement is a successful intervention for relieving chronic @entity2 . However, between 10-30% of @entity0 continue to experience @entity6 after joint replacement. Evidence suggests that a risk factor for @entity6 after joint replacement is the severity of acute post-operative @entity2 . The aim of this @entity1 ( @entity1 ) is to determine if intra-operative local anaesthetic wound infiltration additional to a standard anaesthesia regimen can reduce the severity of @entity2 at 12-months after total knee replacement (TKR) and total hip replacement (THR) for @entity5 . METHODS: 300 TKR @entity0 and 300 THR @entity0 are being recruited into this single-centre double-blind @entity1 . @entity0 are recruited before surgery and randomised to either the standard care group or the intervention group. @entity0 and outcome assessors are blind to treatment allocation throughout the study. The intervention consists of an intra-operative local anaesthetic wound infiltration, consisting of 60 mls of 0.25% @entity7 with 1 in 200,000 adrenaline. @entity0 are assessed on the first 5 days post-operative, and then at 3-months, 6-months and 12-months. The primary outcome is the WOMAC @entity2 Scale, a validated measure of @entity2 at 12-months. Secondary outcomes include @entity2 severity during the in- @entity0 stay, post-operative @entity3 and @entity4 , satisfaction with @entity2 relief, length of hospital stay, @entity2 and disability, @entity2 sensitivity, complications and cost-effectiveness. A nested qualitative study within the @entity1 will examine the acceptability and feasibility of the intervention for both @entity0 and healthcare professionals. DISCUSSION: Large-scale RCTs assessing the effectiveness of a surgical intervention are uncommon, particularly in orthopaedics. The results from this trial will inform evidence-based recommendations for both short-term and long-term @entity2 management after lower limb joint replacement. If a local anaesthetic wound infiltration is found to be an effective and cost-effective intervention, implementation into clinical practice could improve long-term @entity2 outcomes for @entity0 undergoing lower limb joint replacement. TRIAL REGISTRATION: Current Controlled Trials ISRCTN96095682.

title: The effect of local anaesthetic wound infiltration on @entity6 after lower limb joint replacement: a protocol for a double-blind XXXX .

answer: @entity1


abstract: OBJECTIVE: To provide an update on transvaginal mesh procedures, newly available minimally invasive surgical techniques for pelvic floor repair. OPTIONS: The discussion is limited to minimally invasive transvaginal mesh procedures. EVIDENCE: PubMed and Medline were searched for articles published in English, using the key words " @entity3 ," transvaginal mesh," and "minimally invasive surgery." Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Searches were updated on a regular basis, and articles were incorporated in the guideline to May 2010. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. VALUES: The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on the Preventive Health Care. Recommendations for practice were ranked according to the method described in that report (Table 1). BENEFITS, HARMS, AND COSTS: Counselling for the surgical treatment of @entity3 should consider all benefits, harms, and costs of the surgical procedure, with particular emphasis on the use of mesh. RECOMMENDATIONS: 1. @entity0 should be counselled that transvaginal mesh procedures are considered novel techniques for pelvic floor repair that demonstrate high rates of anatomical cure in uncontrolled short-term case series. (II-2B) 2. @entity0 should be informed of the range of success rates until stronger evidence of superiority is published. (II-2B) 3. Training specific to transvaginal mesh procedures should be undertaken before procedures are performed. (III-C) 4. @entity0 should undergo thorough preoperative counselling regarding (a) the potential serious adverse sequelae of transvaginal mesh repairs, including mesh exposure, @entity1 , and @entity2 ; and (b) the limited data available comparing transvaginal mesh systems with traditional vaginal prolapse repairs or with traditional use of graft material in the form of augmented colporrhaphy and sacral colpopexy. (III-C) 5. Until appropriate supportive data are available, new trocarless kits should be considered investigative. (III-C).

title: Transvaginal mesh procedures for XXXX .

answer: @entity3


abstract: BACKGROUND: @entity0 with a recent @entity2 ( @entity2 ) present a reduction in functional capacity expressed as a decrease in peak @entity1 consumption (Vo2 peak). The impact of a Tai Chi Chuan (TCC) cardiac rehabilitation program for @entity0 recovering from recent @entity2 has yet to be assessed. Our goal is to evaluate functional capacity after a TCC-based cardiac rehabilitation program in @entity0 with recent @entity2 . METHODS: A single-blind randomized clinical trial was conducted. The researchers who performed the tests were blinded to group allocation. Between the 14th and 21st days after hospital discharge, all @entity0 performed a cardiopulmonary exercise testing and a laboratory blood workup. Mean age was similar (56  9 years in the TCC group and 60  9 years in the control group). @entity0 allocated to the intervention group performed 3 weekly sessions of TCC Beijin style for 12 weeks (n=31). The control group participated in 3 weekly sessions of full-body stretching exercises (n=30). RESULTS: After the 12-week study period, @entity0 in the TCC group experienced a significant 14% increase in Vo2 peak from baseline (21.6    5.2 to 24.6    5.2 mL/kg per minute), whereas control @entity0 had a nonsignificant 5% decline in Vo2 peak (20.4    5.1 to 19.4    4.4 mL/kg per minute). There was a significant difference between the 2 groups (P<.0001). CONCLUSIONS: Tai Chi Chuan practice was associated with an increase in Vo2 peak in @entity0 with a recent @entity2 and may constitute an effective form of cardiac rehabilitation in this @entity0 population.

title: Tai Chi Chuan improves functional capacity after XXXX : A randomized clinical trial.

answer: @entity2


abstract: Seventeen eyes of 14 @entity0 affected with severe @entity6 underwent surgical treatment with either cryotherapy - 3 eyes - or diathermy - 14 eyes. The indications for surgery were selected as follows: ten eyes of 9 @entity0 showed recurrence(s) or increase of @entity1 following tapering of systemic corticoids; 5 @entity0 had contra-indications to systemic corticoids. Ten eyes had @entity5 . The follow-up after surgery varies from 2,5 years to 10 years with an average of 5 years. Complete and permanent recovery from @entity1 was achieved in 7 eyes (41,2%). Permanent although incomplete improvement was achieved in 4 eyes (23,5%). Recurrences of @entity1 after incomplete improvement occurred in 4 eyes (23,5%). Complications - @entity4 and severe @entity2 - occurred in 2 eyes (11,8%). @entity5 cleared in 9 out of 10 eyes. The final visual acuity was the same or better as compared to the @entity3 . It is concluded that the long term evaluation of cryotherapy and diathermy in the treatment of @entity6 confirms the results achieved in other series with a shorter follow-up. The treatment is beneficial in selected cases of severe @entity6 . However complete and permanent recovery from @entity1 should be expected in less than 50% of the cases.

title: [Diathermy and cryotherapy of the pars plana in the treatment of XXXX . Long-term evaluation].

answer: @entity6


abstract: Although administration of glucocorticoid @entity4 is one of the most widely used therapeutic modalities for the clinical management of acute @entity3 (CNS), controversy continues regarding their effectiveness. In essence, two viewpoints concerning their use exist. Some believe that despite their poor clinical record, the @entity4 nevertheless have a place in the treatment of @entity0 CNS @entity1 . In general, this group of clinical investigators uses the @entity4 primarily out of tradition, feeling that @entity2 therapy may be of some benefit. Unfortunately, confusion remains as to what constitutes an appropriate dose or regimen. In this regard, it has been suggested that the @entity2 dose be increased and the regimen intensified. Others believe that @entity4 should not be used. They contend that in view of their poor clinical record, it is unlikely that increasing the @entity2 dose or changing the dosing regimen will improve clinical efficacy, since @entity4 have already failed at what may be considered huge doses by glucocorticoid standards. Furthermore, it is contended that the side effects associated with large @entity2 doses reduce the margin of safety so as to make the @entity4 unsafe. Complicating these arguments is a body of experimental evidence that by and large strongly supports the utility of @entity4 for the acute treatment of CNS @entity1 . The intent of this article is to evaluate the current use of @entity2 therapy for CNS @entity1 from a purely pharmacological perspective, and to compare the @entity4 ' experimental use with their clinical application.

title: Current application of "high-dose" XXXX therapy for @entity3 . A pharmacological perspective.

answer: @entity2


abstract: Although administration of glucocorticoid @entity4 is one of the most widely used therapeutic modalities for the clinical management of acute @entity3 (CNS), controversy continues regarding their effectiveness. In essence, two viewpoints concerning their use exist. Some believe that despite their poor clinical record, the @entity4 nevertheless have a place in the treatment of @entity0 CNS @entity1 . In general, this group of clinical investigators uses the @entity4 primarily out of tradition, feeling that @entity2 therapy may be of some benefit. Unfortunately, confusion remains as to what constitutes an appropriate dose or regimen. In this regard, it has been suggested that the @entity2 dose be increased and the regimen intensified. Others believe that @entity4 should not be used. They contend that in view of their poor clinical record, it is unlikely that increasing the @entity2 dose or changing the dosing regimen will improve clinical efficacy, since @entity4 have already failed at what may be considered huge doses by glucocorticoid standards. Furthermore, it is contended that the side effects associated with large @entity2 doses reduce the margin of safety so as to make the @entity4 unsafe. Complicating these arguments is a body of experimental evidence that by and large strongly supports the utility of @entity4 for the acute treatment of CNS @entity1 . The intent of this article is to evaluate the current use of @entity2 therapy for CNS @entity1 from a purely pharmacological perspective, and to compare the @entity4 ' experimental use with their clinical application.

title: Current application of "high-dose" @entity2 therapy for XXXX . A pharmacological perspective.

answer: @entity3


abstract: A cluster of seven primary @entity5 was identified in a town of 3000 population during the 10-year period from 1973 to 1982. With six deaths, this represents an age-adjusted mortality rate 4.1 times greater than expected. No other @entity1 were found to be in excess of the anticipated incidence in this town. When @entity5 mortality rates in 36 other towns of approximately the same population were calculated, only one other town was found to have an excessive rate. All seven @entity1 in this study were histologically verified: six were diagnosed as @entity3 multiforme. Interviews were conducted with @entity0 or next-of-kin to obtain the exposure histories of the @entity0 . A number of respondents reported occupational or residential exposure either to a shoe factory or to one of the several @entity6 hatcheries in the town. Many of the @entity0 ate fish from local ponds that had previously been used as coal mining strip pits. Two @entity0 were siblings. None of the @entity0 had a history of significant @entity4 . This unique situation may provide an opportunity to learn more about environmental risk factors for @entity2 . Further epidemiological studies are planned.

title: Epidemiological findings in a XXXX cluster in western Missouri.

answer: @entity5


abstract: BACKGROUND: To determine the optimal single-dose radiotherapy schedule for @entity2 from bone @entity1 in a multi-centre, international, randomised trial. @entity0 AND METHODS: 651 @entity0 were randomised to either 8Gy (n=325) or 4Gy (n=326) radiotherapy. @entity2 at 4, 8, 12, 24 and 52weeks was assessed using a Categorical Scale (CS) and a Visual Analogue Scale (VAS). The primary endpoint was response at 4weeks. RESULTS: There was no significant difference in @entity0 demographics and other co-variates. The complete response (CR) rate and ORR (complete or partial response) for all follow-up times were higher after 8Gy (p=0.02). The Kaplan-Meier actuarial rate (categorical scale) at 4weeks for ORR was 80% after 8Gy compared to 68% after 4Gy (p=0.0015). 117 re-treatments were given of which 72 were in the 4Gy group and 45 in 8Gy arm (p=0.01). CONCLUSIONS: There was a marked consistent difference in @entity2 relief at all time points in favour of 8Gy. These data reinforce the case for single dose 8Gy radiotherapy to be recommended for metastatic @entity2 in all healthcare settings.

title: IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone XXXX .

answer: @entity1


abstract: OBJECTIVE: To investigate the inhibitory effect of bone marrow mesenchymal stem cells (BMSCs) on E coliinduced @entity5 in @entity2 . METHODS: BMSCs were isolated, cultured and amplified by the attached choice method. Fifty SD @entity2 were randomized into five groups of equal number: normal control, @entity8 ( @entity8 ) , chronic @entity5 (CBP), @entity8 + BMSCs, and CBP + BMSCs, and the animals in the latter four groups were injected with @entity4 into both sides of the prostate under ultrasound guidance for 1 - 14 days to induce @entity8 and for 4 - 12 weeks to induce CBP. The control @entity2 were injected with the same amount of PBS. Two weeks after injection of BMSCs into the prostates, pathomorphological changes in the prostate were observed under the light microscope and the mRNA and protein levels of @entity7 and @entity6 determined by RT-PCR and ELISA, respectively, followed by statistical analysis with SPSS 18.0. RESULTS: Histopathological evaluation showed typical pathological inflammatory changes in the prostates of the @entity2 in the @entity8 and CBP groups, including glandular structural changes, interstitial @entity0 , @entity1 , and @entity3 , which were all remarkably relieved after treated with BMSCs. The mRNA and protein levels of IL-b ([0.829    0.121] and [271.75    90.59] pg/ml) and @entity6 ([0.913    0. 094] and [105.78    19. 05] pg/ml) in the @entity8 and those of @entity7 ([0. 975    0. 114] and [265. 31    71. 34] pg/ml) and @entity6 ([0. 886    0. 084] and [107. 45    26. 11 ] pg/ml) in the CBP groups were significantly higher than those in the control @entity2 ([0. 342    0.087] and [45.76 17. 99] pg/ml, P <0. 05); ([0.247    0.054] and ([19.42    7. 75] pg/ml, P <0. 01) as well as than those in the @entity8 + BMSCs ([0. 433    0. 072] and [51. 34    22. 13] pg/ml, P < 0. 05 ) ; ( [0. 313    0. 076] and [28. 38    8. 78] pg/ml, P < 0. 01) and the CBP + BMSCs group ([0.396    0.064] and [56.37    21.22] pg/ml, P <0.05); ([0.417    0.068] and [29.21    10.22] pg/ml, P <0.01). CONCLUSION: Injection of BMSCs can reduce @entity4 -induced @entity5 reaction, which.may be associated with its reduction of @entity1 and the expressions of @entity7 and @entity6 in the prostate tissue.

title: [Bone marrow mesenchymal stem cells suppress XXXX -induced @entity5 in @entity2 ].

answer: @entity4


abstract: OBJECTIVE: To investigate the inhibitory effect of bone marrow mesenchymal stem cells (BMSCs) on E coliinduced @entity5 in @entity2 . METHODS: BMSCs were isolated, cultured and amplified by the attached choice method. Fifty SD @entity2 were randomized into five groups of equal number: normal control, @entity8 ( @entity8 ) , chronic @entity5 (CBP), @entity8 + BMSCs, and CBP + BMSCs, and the animals in the latter four groups were injected with @entity4 into both sides of the prostate under ultrasound guidance for 1 - 14 days to induce @entity8 and for 4 - 12 weeks to induce CBP. The control @entity2 were injected with the same amount of PBS. Two weeks after injection of BMSCs into the prostates, pathomorphological changes in the prostate were observed under the light microscope and the mRNA and protein levels of @entity7 and @entity6 determined by RT-PCR and ELISA, respectively, followed by statistical analysis with SPSS 18.0. RESULTS: Histopathological evaluation showed typical pathological inflammatory changes in the prostates of the @entity2 in the @entity8 and CBP groups, including glandular structural changes, interstitial @entity0 , @entity1 , and @entity3 , which were all remarkably relieved after treated with BMSCs. The mRNA and protein levels of IL-b ([0.829    0.121] and [271.75    90.59] pg/ml) and @entity6 ([0.913    0. 094] and [105.78    19. 05] pg/ml) in the @entity8 and those of @entity7 ([0. 975    0. 114] and [265. 31    71. 34] pg/ml) and @entity6 ([0. 886    0. 084] and [107. 45    26. 11 ] pg/ml) in the CBP groups were significantly higher than those in the control @entity2 ([0. 342    0.087] and [45.76 17. 99] pg/ml, P <0. 05); ([0.247    0.054] and ([19.42    7. 75] pg/ml, P <0. 01) as well as than those in the @entity8 + BMSCs ([0. 433    0. 072] and [51. 34    22. 13] pg/ml, P < 0. 05 ) ; ( [0. 313    0. 076] and [28. 38    8. 78] pg/ml, P < 0. 01) and the CBP + BMSCs group ([0.396    0.064] and [56.37    21.22] pg/ml, P <0.05); ([0.417    0.068] and [29.21    10.22] pg/ml, P <0.01). CONCLUSION: Injection of BMSCs can reduce @entity4 -induced @entity5 reaction, which.may be associated with its reduction of @entity1 and the expressions of @entity7 and @entity6 in the prostate tissue.

title: [Bone marrow mesenchymal stem cells suppress @entity4 -induced XXXX in @entity2 ].

answer: @entity5


abstract: OBJECTIVE: To investigate the inhibitory effect of bone marrow mesenchymal stem cells (BMSCs) on E coliinduced @entity5 in @entity2 . METHODS: BMSCs were isolated, cultured and amplified by the attached choice method. Fifty SD @entity2 were randomized into five groups of equal number: normal control, @entity8 ( @entity8 ) , chronic @entity5 (CBP), @entity8 + BMSCs, and CBP + BMSCs, and the animals in the latter four groups were injected with @entity4 into both sides of the prostate under ultrasound guidance for 1 - 14 days to induce @entity8 and for 4 - 12 weeks to induce CBP. The control @entity2 were injected with the same amount of PBS. Two weeks after injection of BMSCs into the prostates, pathomorphological changes in the prostate were observed under the light microscope and the mRNA and protein levels of @entity7 and @entity6 determined by RT-PCR and ELISA, respectively, followed by statistical analysis with SPSS 18.0. RESULTS: Histopathological evaluation showed typical pathological inflammatory changes in the prostates of the @entity2 in the @entity8 and CBP groups, including glandular structural changes, interstitial @entity0 , @entity1 , and @entity3 , which were all remarkably relieved after treated with BMSCs. The mRNA and protein levels of IL-b ([0.829    0.121] and [271.75    90.59] pg/ml) and @entity6 ([0.913    0. 094] and [105.78    19. 05] pg/ml) in the @entity8 and those of @entity7 ([0. 975    0. 114] and [265. 31    71. 34] pg/ml) and @entity6 ([0. 886    0. 084] and [107. 45    26. 11 ] pg/ml) in the CBP groups were significantly higher than those in the control @entity2 ([0. 342    0.087] and [45.76 17. 99] pg/ml, P <0. 05); ([0.247    0.054] and ([19.42    7. 75] pg/ml, P <0. 01) as well as than those in the @entity8 + BMSCs ([0. 433    0. 072] and [51. 34    22. 13] pg/ml, P < 0. 05 ) ; ( [0. 313    0. 076] and [28. 38    8. 78] pg/ml, P < 0. 01) and the CBP + BMSCs group ([0.396    0.064] and [56.37    21.22] pg/ml, P <0.05); ([0.417    0.068] and [29.21    10.22] pg/ml, P <0.01). CONCLUSION: Injection of BMSCs can reduce @entity4 -induced @entity5 reaction, which.may be associated with its reduction of @entity1 and the expressions of @entity7 and @entity6 in the prostate tissue.

title: [Bone marrow mesenchymal stem cells suppress @entity4 -induced @entity5 in XXXX ].

answer: @entity2


abstract: A retrospective analysis of the University of Minnesota (Minneapolis) experience with @entity3 is presented. Seventy-five @entity0 were diagnosed with @entity3 between 1958 and 1983, of which 53 (71%) had at least one Reese-Ellsworth group V eye. Nineteen group V @entity0 and one group II @entity0 developed @entity2 recurrence. The cumulative actuarial rate of recurrence at 12 years was 36% for @entity0 with group V disease. The median time from diagnosis to recurrence for unilateral @entity0 was seven months and for bilateral @entity0 28 months (P = .001). @entity0 developing @entity2 had a 10-year actuarial survival rate postrecurrence of 34%. The four long-term survivors of extraocular recurrences had had isolated orbital or local soft tissue recurrences only. Features of group V @entity0 associated with extraocular recurrences were identified by univariate life table analyses. Clinical poor-risk factors included the nongenetic form of the disease (P = .03) and male sex (P = .02). Pathologic poor risk factors included rubeosis (P = .01), undifferentiated histology (P = .03), large @entity1 size (P = .05), and intraocular extension to the anterior segment (P = .02), retinal pigment epithelium (P = .03), choroid (P less than .001), and optic nerve beyond the lamina cribrosa (P = .02). Treatment-associated poor-risk factors included an optic nerve length of less than 5 mm removed at enucleation (P = .003). Multivariate life table analyses demonstrated the following parameters to be independent poor-prognostic factors: optic nerve length of less than 5 mm removed at enucleation (P = .001), optic nerve involvement (P = .004), and large @entity1 size (P = .01). These results will help to identify @entity0 with @entity3 who are at greatest risk for extraocular recurrence.

title: XXXX group V: an analysis of prognostic factors.

answer: @entity3


abstract: BACKGROUND: The diagnostic accuracy of flat panel digital detector (FPDD) cinefluoroscopy for coronary artery @entity1 (CAC) detection, compared to multiple detector computed tomography (MDCT), is not known. METHODS: CAC was assessed by FPDD cinefluoroscopy (graded as 0,1, 2 and 3) and @entity1 score (CACS) was determined by MDCT in 151 asymptomatic individuals of low to intermediate cardiovascular risk, 40-60 years old (mean age 53.1    7.4, @entity0 76.5%). RESULTS: CAC was detected by MDCT and cinefluoroscopy in 79 (52.3%) and 69 (45.7%) of cases respectively. Agreement between MDCT and cinefluoroscopy was 77.5% (weighted kappa coefficient 0.75). Cinefluoroscopy was able to detect CAC in 50% of subjects with minimal CACS (<10). For CACS=0, area under the curve (AUC) was 0.89 (95% CI 0.83-0.93, p=0.0001) with sensitivity 82.3% and specificity 94.4%. For CACS=10, AUC was 0.91 (95% CI 0.86-0.95, p=0.0001) with sensitivity 91.8% and specificity 85.6%. For CACS=400, AUC was 0.97 (95% CI 0.94-0.99, p=0.0001) with sensitivity 100% and specificity 88.7%. The effective radiation dose was 1.8    0.09 @entity2 for CT and 0.26    0.13 @entity2 for cinefluoroscopy. CONCLUSIONS: Cinefluoroscopy performed with 'state-of-the art' FPDD technology has an excellent diagnostic accuracy compared to the 'gold standard' MDCT for CAC detection in middle aged, low to intermediate cardiovascular risk, asymptomatic individuals, with the advantage of lower radiation exposure.

title: Coronary artery XXXX detection using flat panel digital cinefluoroscopy: comparison to coronary artery @entity1 score assessed with multiple detector computerized tomography.

answer: @entity1


abstract: BACKGROUND: The diagnostic accuracy of flat panel digital detector (FPDD) cinefluoroscopy for coronary artery @entity1 (CAC) detection, compared to multiple detector computed tomography (MDCT), is not known. METHODS: CAC was assessed by FPDD cinefluoroscopy (graded as 0,1, 2 and 3) and @entity1 score (CACS) was determined by MDCT in 151 asymptomatic individuals of low to intermediate cardiovascular risk, 40-60 years old (mean age 53.1    7.4, @entity0 76.5%). RESULTS: CAC was detected by MDCT and cinefluoroscopy in 79 (52.3%) and 69 (45.7%) of cases respectively. Agreement between MDCT and cinefluoroscopy was 77.5% (weighted kappa coefficient 0.75). Cinefluoroscopy was able to detect CAC in 50% of subjects with minimal CACS (<10). For CACS=0, area under the curve (AUC) was 0.89 (95% CI 0.83-0.93, p=0.0001) with sensitivity 82.3% and specificity 94.4%. For CACS=10, AUC was 0.91 (95% CI 0.86-0.95, p=0.0001) with sensitivity 91.8% and specificity 85.6%. For CACS=400, AUC was 0.97 (95% CI 0.94-0.99, p=0.0001) with sensitivity 100% and specificity 88.7%. The effective radiation dose was 1.8    0.09 @entity2 for CT and 0.26    0.13 @entity2 for cinefluoroscopy. CONCLUSIONS: Cinefluoroscopy performed with 'state-of-the art' FPDD technology has an excellent diagnostic accuracy compared to the 'gold standard' MDCT for CAC detection in middle aged, low to intermediate cardiovascular risk, asymptomatic individuals, with the advantage of lower radiation exposure.

title: Coronary artery @entity1 detection using flat panel digital cinefluoroscopy: comparison to coronary artery XXXX score assessed with multiple detector computerized tomography.

answer: @entity1


abstract: BACKGROUND: @entity2 is associated with skeletal muscle proteolysis, and alkali supplementation has shown improvements in lean body mass and urinary @entity4 wasting in several studies. However, the association of @entity2 with functional outcomes has not been examined on a population-based level. STUDY DESIGN: Cross-sectional study. SETTING _ @entity0 : 2,675 nationally representative adults 50 years or older in the National Health and Nutrition Examination Survey 1999-2002. FACTOR: Serum @entity5 level. OUTCOMES: Low gait speed and low peak torque were defined as being in the lowest sex-specific quartile of gait speed and peak torque, respectively. MEASUREMENTS: Serum @entity5 was measured in all @entity0 . Gait speed was determined from a 20-foot timed walk. Peak torque was calculated using peak isokinetic knee extensor force. RESULTS: Serum @entity5 level <23 mEq/L was present in 22.7% of the cohort. Compared with @entity0 with @entity5 levels >= 23 mEq/L, those with @entity5 levels <23 mEq/L had higher body mass index and serum albumin levels; were more likely to have low socioeconomic status, a diagnosis of @entity1 , or glomerular filtration rate <60 mL/ @entity3 .73 m(2); and were less likely to use diuretics. Serum @entity5 level <23 mEq/L compared with >= 23 mEq/L was associated with low gait speed (OR, 1.43; 95% CI, 1.04-1.95) and low peak torque (OR, 1.36; 95% CI, 1.07-1.74) after multivariable adjustment. The association with low peak torque was modified by race/ethnicity in @entity0 , but not @entity0 (ORs, 1.52 [95% CI, 1.08-2.13] for @entity0 , 2.33 [95% CI, 1.23-4.44] for nonwhite @entity0 , and 0.93 [95% CI, 0.47-1.82] for white @entity0 ). LIMITATIONS: Cross-sectional study using a single @entity5 measurement. CONCLUSIONS: Lower serum @entity5 levels are associated with slower gait speed and decreased quadriceps strength in older adults. Further studies should examine the effect of alkali therapy on functional outcomes.

title: Association of serum XXXX levels with gait speed and quadriceps strength in older adults.

answer: @entity5


abstract: OBJECTIVE: This study aimed to evaluate self-reported cognitive functioning of postmenopausal @entity0 @entity1 before and during endocrine treatment compared with healthy female controls, and to investigate associations between self-reported cognitive functioning, cognitive test performance and @entity3 / @entity4 , @entity6 , and menopausal complaints. METHODS: Self-reported cognitive functioning, @entity3 / @entity4 , @entity6 , menopausal complaints, and cognitive tests performance were assessed before (T1) and after 1 year (T2) of adjuvant endocrine treatment in postmenopausal chemotherapy-na  ve @entity0 @entity1 . Self-reported cognitive functioning was assessed by the @entity2 questionnaire and interview questions concerning cognitive complaints. @entity1 participated in the TEAM-trial, a prospective randomized study investigating @entity5 versus @entity7 as adjuvant therapy for hormone-sensitive @entity0 . Identical information was obtained from healthy postmenopausal volunteers. RESULTS: Two measures for self-reported cognitive functioning provided the distinctive results. At T1 and T2, healthy controls reported a higher frequency of @entity2 than @entity1 ; change over time did not differ between groups. The prevalence of cognitive complaints did not differ between the groups at T1, but change over time regarding attention/concentration complaints differed between groups, due to an increased prevalence in @entity5 users. Self-reported cognitive functioning showed moderate associations with @entity3 / @entity4 , @entity6 , and menopausal complaints. Cognitive test performance was not associated with self-reported cognitive functioning, but weakly with @entity3 / @entity4 and @entity6 . CONCLUSION: Adjuvant therapy with @entity5 and @entity7 did not influence the self-reported frequency of @entity2 . Increased attention/concentration complaints were observed in @entity5 users, but not in @entity7 users. This latter finding should be confirmed with better validated instruments.

title: Self-reported cognitive functioning in postmenopausal XXXX @entity1 before and during endocrine treatment: findings from the neuropsychological TEAM side-study.

answer: @entity0


abstract: OBJECTIVE: This study aimed to evaluate self-reported cognitive functioning of postmenopausal @entity0 @entity1 before and during endocrine treatment compared with healthy female controls, and to investigate associations between self-reported cognitive functioning, cognitive test performance and @entity3 / @entity4 , @entity6 , and menopausal complaints. METHODS: Self-reported cognitive functioning, @entity3 / @entity4 , @entity6 , menopausal complaints, and cognitive tests performance were assessed before (T1) and after 1 year (T2) of adjuvant endocrine treatment in postmenopausal chemotherapy-na  ve @entity0 @entity1 . Self-reported cognitive functioning was assessed by the @entity2 questionnaire and interview questions concerning cognitive complaints. @entity1 participated in the TEAM-trial, a prospective randomized study investigating @entity5 versus @entity7 as adjuvant therapy for hormone-sensitive @entity0 . Identical information was obtained from healthy postmenopausal volunteers. RESULTS: Two measures for self-reported cognitive functioning provided the distinctive results. At T1 and T2, healthy controls reported a higher frequency of @entity2 than @entity1 ; change over time did not differ between groups. The prevalence of cognitive complaints did not differ between the groups at T1, but change over time regarding attention/concentration complaints differed between groups, due to an increased prevalence in @entity5 users. Self-reported cognitive functioning showed moderate associations with @entity3 / @entity4 , @entity6 , and menopausal complaints. Cognitive test performance was not associated with self-reported cognitive functioning, but weakly with @entity3 / @entity4 and @entity6 . CONCLUSION: Adjuvant therapy with @entity5 and @entity7 did not influence the self-reported frequency of @entity2 . Increased attention/concentration complaints were observed in @entity5 users, but not in @entity7 users. This latter finding should be confirmed with better validated instruments.

title: Self-reported cognitive functioning in postmenopausal @entity0 XXXX before and during endocrine treatment: findings from the neuropsychological TEAM side-study.

answer: @entity1


abstract: PURPOSE: Soft tissue @entity4 is reported in up to 26% of @entity0 undergoing radiotherapy for @entity1 . Management options include local irrigation, wound debridement, antibiotics, anti-inflammatory medication, and analgesics. @entity5 may be treated with partial penectomy. Hyperbaric @entity3 therapy (HBO) has a well-defined role in the treatment of late radiation @entity7 . We present experience with HBO for medically @entity10 after penile brachytherapy. METHODS AND MATERIALS: From November 2001 to January 2009, 7 @entity0 of 43 treated with penile brachytherapy for @entity8 developed @entity10 and were treated with HBO. All had received a prescribed dose of 60 Gy through interstitial brachytherapy using Paris system guidelines. All had failed conservative medical therapies for soft tissue @entity4 . RESULTS: Median age was 55 years (range, 35-72 years). Comorbidities potentially effecting wound healing included @entity6 (2), current smokers (5), former smoker (1) but no @entity2 , or @entity9 . Median time between completion of brachytherapy and appearance of soft tissue @entity4 was 13 months (range, 9-24 months) and the median interval before starting HBO was 7.5 months (range, 3-13 months). The median number of "dives" per HBO course was 40 (30-53). All 7 experienced an excellent response with healing of the @entity4 and resolution of symptoms, although 3 required an additional course, 2 for consolidation of healing, and 1 for a relapse 4 months later. No @entity0 was submitted to penectomy. CONCLUSIONS: HBO should be considered as a treatment option in @entity0 with @entity10 of the penis after brachytherapy.

title: The efficacy of hyperbaric XXXX therapy in the treatment of medically @entity10 after penile brachytherapy.

answer: @entity3


abstract: PURPOSE: Soft tissue @entity4 is reported in up to 26% of @entity0 undergoing radiotherapy for @entity1 . Management options include local irrigation, wound debridement, antibiotics, anti-inflammatory medication, and analgesics. @entity5 may be treated with partial penectomy. Hyperbaric @entity3 therapy (HBO) has a well-defined role in the treatment of late radiation @entity7 . We present experience with HBO for medically @entity10 after penile brachytherapy. METHODS AND MATERIALS: From November 2001 to January 2009, 7 @entity0 of 43 treated with penile brachytherapy for @entity8 developed @entity10 and were treated with HBO. All had received a prescribed dose of 60 Gy through interstitial brachytherapy using Paris system guidelines. All had failed conservative medical therapies for soft tissue @entity4 . RESULTS: Median age was 55 years (range, 35-72 years). Comorbidities potentially effecting wound healing included @entity6 (2), current smokers (5), former smoker (1) but no @entity2 , or @entity9 . Median time between completion of brachytherapy and appearance of soft tissue @entity4 was 13 months (range, 9-24 months) and the median interval before starting HBO was 7.5 months (range, 3-13 months). The median number of "dives" per HBO course was 40 (30-53). All 7 experienced an excellent response with healing of the @entity4 and resolution of symptoms, although 3 required an additional course, 2 for consolidation of healing, and 1 for a relapse 4 months later. No @entity0 was submitted to penectomy. CONCLUSIONS: HBO should be considered as a treatment option in @entity0 with @entity10 of the penis after brachytherapy.

title: The efficacy of hyperbaric @entity3 therapy in the treatment of medically XXXX after penile brachytherapy.

answer: @entity10


abstract: BACKGROUND: Preimplantation cross-talk between a functional blastocyst and the endometrium is critical for successful blastocyst implantation. This interaction is mediated in part by endometrial cytokines/growth factors secreted by glandular epithelium into the uterine cavity. Recent evidence suggests that blastocyst-derived @entity6 may influence the endometrial milieu in conception cycles thereby enhancing receptivity and implantation success. This study investigated the effect of @entity6 on the secretory profile of a select cohort of 44 cytokines/growth factors from primary @entity0 endometrial epithelial cells (hEECs). These factors included those with both known and unknown roles during receptivity and implantation. The expression of one previously unknown @entity6 -regulated factor, @entity2 ( @entity2 ), in @entity0 endometrium and its effects on hEEC function were further examined. METHODS: hEECs isolated from endometrial biopsies collected from fertile cycling @entity0 (n = 15) were treated    recombinant @entity6 (0.2-20 IU/ml) for 48 h and conditioned media was quantitatively analysed using Luminex    multiplex technology. @entity2 was further investigated by immunohistochemistry, western blot and cell-adhesion assays. RESULTS: Of 44 cytokines/growth factors examined, 39 were produced by hEECs with a distinct profile. @entity6 (2 IU/ml) significantly increased the production of six factors, including those with known roles in receptivity and trophoblast function ( @entity7 ), blastocyst migration and adhesion ( @entity1 ), blastocyst development ( @entity5 ) and one unknown with respect to receptivity and implantation ( @entity2 ). Up-regulation of known @entity6 -regulated proteins, vascular endothelial growth factor and @entity4 inhibitory factor, validated this study. Immunoreactive epithelial @entity2 increased across the menstrual cycle, being highest in secretory and first trimester pregnancy endometrium in vivo. @entity2 (100 ng/ml) stimulated phosphorylation of @entity3 in hEEC with no effect on @entity3 abundance and stimulated hEEC adhesion to fibronectin and collagen IV (components of blastocyst/trophectoderm extracellular matrix). CONCLUSIONS: These findings clearly support roles for @entity6 and @entity2 in the blastocyst-endometrial cross-talk important for endometrial receptivity and blastocyst implantation.

title: @entity0 chorionic gonadotrophin regulates XXXX and other cytokines produced by @entity0 endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity.

answer: @entity2


abstract: BACKGROUND: Preimplantation cross-talk between a functional blastocyst and the endometrium is critical for successful blastocyst implantation. This interaction is mediated in part by endometrial cytokines/growth factors secreted by glandular epithelium into the uterine cavity. Recent evidence suggests that blastocyst-derived @entity6 may influence the endometrial milieu in conception cycles thereby enhancing receptivity and implantation success. This study investigated the effect of @entity6 on the secretory profile of a select cohort of 44 cytokines/growth factors from primary @entity0 endometrial epithelial cells (hEECs). These factors included those with both known and unknown roles during receptivity and implantation. The expression of one previously unknown @entity6 -regulated factor, @entity2 ( @entity2 ), in @entity0 endometrium and its effects on hEEC function were further examined. METHODS: hEECs isolated from endometrial biopsies collected from fertile cycling @entity0 (n = 15) were treated    recombinant @entity6 (0.2-20 IU/ml) for 48 h and conditioned media was quantitatively analysed using Luminex    multiplex technology. @entity2 was further investigated by immunohistochemistry, western blot and cell-adhesion assays. RESULTS: Of 44 cytokines/growth factors examined, 39 were produced by hEECs with a distinct profile. @entity6 (2 IU/ml) significantly increased the production of six factors, including those with known roles in receptivity and trophoblast function ( @entity7 ), blastocyst migration and adhesion ( @entity1 ), blastocyst development ( @entity5 ) and one unknown with respect to receptivity and implantation ( @entity2 ). Up-regulation of known @entity6 -regulated proteins, vascular endothelial growth factor and @entity4 inhibitory factor, validated this study. Immunoreactive epithelial @entity2 increased across the menstrual cycle, being highest in secretory and first trimester pregnancy endometrium in vivo. @entity2 (100 ng/ml) stimulated phosphorylation of @entity3 in hEEC with no effect on @entity3 abundance and stimulated hEEC adhesion to fibronectin and collagen IV (components of blastocyst/trophectoderm extracellular matrix). CONCLUSIONS: These findings clearly support roles for @entity6 and @entity2 in the blastocyst-endometrial cross-talk important for endometrial receptivity and blastocyst implantation.

title: XXXX chorionic gonadotrophin regulates @entity2 and other cytokines produced by @entity0 endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity.

answer: @entity0


abstract: BACKGROUND: Preimplantation cross-talk between a functional blastocyst and the endometrium is critical for successful blastocyst implantation. This interaction is mediated in part by endometrial cytokines/growth factors secreted by glandular epithelium into the uterine cavity. Recent evidence suggests that blastocyst-derived @entity6 may influence the endometrial milieu in conception cycles thereby enhancing receptivity and implantation success. This study investigated the effect of @entity6 on the secretory profile of a select cohort of 44 cytokines/growth factors from primary @entity0 endometrial epithelial cells (hEECs). These factors included those with both known and unknown roles during receptivity and implantation. The expression of one previously unknown @entity6 -regulated factor, @entity2 ( @entity2 ), in @entity0 endometrium and its effects on hEEC function were further examined. METHODS: hEECs isolated from endometrial biopsies collected from fertile cycling @entity0 (n = 15) were treated    recombinant @entity6 (0.2-20 IU/ml) for 48 h and conditioned media was quantitatively analysed using Luminex    multiplex technology. @entity2 was further investigated by immunohistochemistry, western blot and cell-adhesion assays. RESULTS: Of 44 cytokines/growth factors examined, 39 were produced by hEECs with a distinct profile. @entity6 (2 IU/ml) significantly increased the production of six factors, including those with known roles in receptivity and trophoblast function ( @entity7 ), blastocyst migration and adhesion ( @entity1 ), blastocyst development ( @entity5 ) and one unknown with respect to receptivity and implantation ( @entity2 ). Up-regulation of known @entity6 -regulated proteins, vascular endothelial growth factor and @entity4 inhibitory factor, validated this study. Immunoreactive epithelial @entity2 increased across the menstrual cycle, being highest in secretory and first trimester pregnancy endometrium in vivo. @entity2 (100 ng/ml) stimulated phosphorylation of @entity3 in hEEC with no effect on @entity3 abundance and stimulated hEEC adhesion to fibronectin and collagen IV (components of blastocyst/trophectoderm extracellular matrix). CONCLUSIONS: These findings clearly support roles for @entity6 and @entity2 in the blastocyst-endometrial cross-talk important for endometrial receptivity and blastocyst implantation.

title: @entity0 chorionic gonadotrophin regulates @entity2 and other cytokines produced by XXXX endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity.

answer: @entity0


abstract: Inactivated @entity5 (ORFV, parapoxvirus ovis) induces antiviral activity in animal models of @entity6 and exerts strong effects on @entity0 immune cells. ORFV activates @entity2 ( @entity2 ) via @entity3 and, probably, Toll-like receptor signalling, and triggers the release of @entity1 that has been identified as the key mediator of the antiviral activity. After delineating virus proteins as being the most likely active constituent, we aimed to characterize the ORFV proteins responsible for the therapeutic effect. By using a @entity4 /ORFV expression library we identified several multi-gene DNA fragments with strong immunomodulatory activity. Together these fragments contain 27 ORFs. The encoded proteins are related to virion structure and transcription but are otherwise unrelated. Two proteins were separately expressed and purified, and demonstrated immunostimulatory activity. Gene expression profiles induced by ORFV and the identified fragments were investigated by microarray analysis. Interestingly, all active fragments induced a similar gene-expression pattern, differing only in quantitative aspects. Obviously, several proteins of ORFV activate similar cellular pathways, modulating @entity2 to generate a strong T-helper 1-dominated immune response. This was balanced by additional induction of immune dampening mechanisms, suggesting regulatory differences compared to single cytokine therapies. We conclude that ORFV may have the potential to enrich the armamentarium of antiviral therapies.

title: Characterization of immunostimulatory components of XXXX (parapoxvirus ovis).

answer: @entity5


abstract: @entity5 ( @entity5 ) is a severe @entity3 condition of undetermined brain underpinnings, which involves profound emotion regulation @entity2 . To elucidate biopsychological markers of the disorder, we performed two studies: i.) assessing empathy and social cognition and ii.) measuring the psychophysical properties and functional brain correlates of empathic functioning in a total of fifty-one affected @entity0 and 50 age- and gender-matched controls. In the behavioral study we applied the Multifaceted Empathy Test (MET), a new, ecologically valid measure to assess cognitive (i.e., social cognition) and emotional (i.e., empathic concern) empathy to a subset of @entity0 . In the second study, functional Magnetic Resonance Imaging and skin conductance measurements were performed while @entity0 took a scanner-adapted version of the MET. @entity0 with @entity5 showed impairments in @entity2 . Brain responses during cognitive empathy were significantly reduced in @entity0 compared to controls in the left superior temporal sulcus and gyrus ( @entity4 / @entity6 ), where this reduction was associated with levels of intrusive symptomatology in the @entity5 group. During emotional empathy, @entity0 with @entity5 exhibited greater brain activity than controls in the right middle insular cortex, a response that was associated with skin conductance responses in the @entity0 . Results indicate that altered functioning of the @entity4 / @entity6 and insula represents pathophysiological mediators for reduced empathy in @entity5 , with an important role for intrusive symptomatology and levels of arousal. The findings thus support a conceptualization of @entity5 as @entity1 in both inferring others' mental states and being emotionally attuned to another @entity0 .

title: Neuronal correlates of @entity2 in XXXX .

answer: @entity5


abstract: @entity5 ( @entity5 ) is a severe @entity3 condition of undetermined brain underpinnings, which involves profound emotion regulation @entity2 . To elucidate biopsychological markers of the disorder, we performed two studies: i.) assessing empathy and social cognition and ii.) measuring the psychophysical properties and functional brain correlates of empathic functioning in a total of fifty-one affected @entity0 and 50 age- and gender-matched controls. In the behavioral study we applied the Multifaceted Empathy Test (MET), a new, ecologically valid measure to assess cognitive (i.e., social cognition) and emotional (i.e., empathic concern) empathy to a subset of @entity0 . In the second study, functional Magnetic Resonance Imaging and skin conductance measurements were performed while @entity0 took a scanner-adapted version of the MET. @entity0 with @entity5 showed impairments in @entity2 . Brain responses during cognitive empathy were significantly reduced in @entity0 compared to controls in the left superior temporal sulcus and gyrus ( @entity4 / @entity6 ), where this reduction was associated with levels of intrusive symptomatology in the @entity5 group. During emotional empathy, @entity0 with @entity5 exhibited greater brain activity than controls in the right middle insular cortex, a response that was associated with skin conductance responses in the @entity0 . Results indicate that altered functioning of the @entity4 / @entity6 and insula represents pathophysiological mediators for reduced empathy in @entity5 , with an important role for intrusive symptomatology and levels of arousal. The findings thus support a conceptualization of @entity5 as @entity1 in both inferring others' mental states and being emotionally attuned to another @entity0 .

title: Neuronal correlates of XXXX in @entity5 .

answer: @entity2


abstract: BACKGROUND: A new category of @entity1 ( @entity1 ) has been added in the most recent American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines, since multidrug-resistant (MDR) pathogens are more common in @entity0 with @entity1 than in those with @entity2 ( @entity2 ). The optimal empirical management of @entity0 with @entity1 remains controversial and adherence to guidelines is inconsistent. METHODS: A retrospective cohort study of 3295 adults admitted for @entity1 in an academic centre of Canada, between 1997 and 2008. RESULTS: MDR pathogens were more common among @entity0 with @entity1 than in those with @entity2 , but less so than in other studies. Compared with @entity0 with @entity2 , those with @entity1 had a higher all-cause 30 day mortality [68/563 (12%) versus 201/2732 (7%); P < 0.001] and more frequent need for mechanical ventilation [78/563 (14%) versus 276/2732 (10%); P = 0.01]. In @entity0 with @entity2 , mortality was lower when treatment was concordant with guidelines [86/1557 (6%) versus 109/1097 (10%) if discordant; adjusted odds ratio 0.6 (0.4-0.8); P < 0.001]. In @entity1 , mortality was similar whether or not empirical treatment was concordant with guidelines [6/35 (17%) versus 18/148 (12%) if discordant; P = 0.4]. However, 30 day mortality tended to be higher when the empirical treatment was microbiologically ineffective [4/22 (18%) versus 17/187 (9%) when effective; P = 0.3]. CONCLUSIONS: @entity1 is associated with worse outcomes than @entity2 . MDR pathogens were implicated in only a small fraction of @entity1 cases. In our study, unlike @entity2 , non-respect of current @entity1 guidelines had no adverse effect on the ultimate outcome. Strategies for the empirical management of @entity1 should be tailored to the local epidemiological context.

title: Impact of guideline-consistent therapy on outcome of @entity0 with healthcare-associated and XXXX .

answer: @entity2


abstract: BACKGROUND: A new category of @entity1 ( @entity1 ) has been added in the most recent American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines, since multidrug-resistant (MDR) pathogens are more common in @entity0 with @entity1 than in those with @entity2 ( @entity2 ). The optimal empirical management of @entity0 with @entity1 remains controversial and adherence to guidelines is inconsistent. METHODS: A retrospective cohort study of 3295 adults admitted for @entity1 in an academic centre of Canada, between 1997 and 2008. RESULTS: MDR pathogens were more common among @entity0 with @entity1 than in those with @entity2 , but less so than in other studies. Compared with @entity0 with @entity2 , those with @entity1 had a higher all-cause 30 day mortality [68/563 (12%) versus 201/2732 (7%); P < 0.001] and more frequent need for mechanical ventilation [78/563 (14%) versus 276/2732 (10%); P = 0.01]. In @entity0 with @entity2 , mortality was lower when treatment was concordant with guidelines [86/1557 (6%) versus 109/1097 (10%) if discordant; adjusted odds ratio 0.6 (0.4-0.8); P < 0.001]. In @entity1 , mortality was similar whether or not empirical treatment was concordant with guidelines [6/35 (17%) versus 18/148 (12%) if discordant; P = 0.4]. However, 30 day mortality tended to be higher when the empirical treatment was microbiologically ineffective [4/22 (18%) versus 17/187 (9%) when effective; P = 0.3]. CONCLUSIONS: @entity1 is associated with worse outcomes than @entity2 . MDR pathogens were implicated in only a small fraction of @entity1 cases. In our study, unlike @entity2 , non-respect of current @entity1 guidelines had no adverse effect on the ultimate outcome. Strategies for the empirical management of @entity1 should be tailored to the local epidemiological context.

title: Impact of guideline-consistent therapy on outcome of XXXX with healthcare-associated and @entity2 .

answer: @entity0


abstract: INTRODUCTION: Primary @entity8 ( @entity8 ) of the esophagus is an uncommon @entity2 characterized by a diffuse mixture of squamous and mucus-secreting @entity4 cells. Its biological behavior and response to therapies have not been well studied. Surgical resection is still the primary treatment, but the prognosis is poor. This retrospective study was designed to investigate the clinical characteristics, diagnosis, treatment, and prognosis of primary esophageal @entity8 . METHODS: Clinical data were retrospectively analyzed from 36 @entity0 with pathologically confirmed primary esophageal @entity8 who underwent transthoracic esophagectomy with lymphadenectomy between January 1991 and June 2010 at the @entity2 Hospital of Shantou University Medical College. There were 27 @entity0 and 9 @entity0 ranging in age from 40 to 78 years (median, 58 years). Twenty-six of the 36 @entity0 were treated with surgery alone. The other 10 were treated with surgery plus postoperative radiotherapy. The Kaplan-Meier and log-rank methods were used to estimate and compare survival rates. Cox's hazard regression model was used to identify prognostic factors, with entry factors of gender, age ( <=60 years versus >60 years), length of the @entity3 ( <=5 cm versus >5 cm), location of the @entity3 , macroscopic @entity2 type, @entity2 cell differentiation, pT, pN, pTNM stage, operation type (radical/palliative), and radiotherapy (yes/no). RESULTS: The clinical symptoms, radiological and endoscopic features of primary esophageal @entity8 were similar to those of @entity7 ( @entity7 ). Of the 20 cases who underwent preoperative endoscopic biopsy, 18 cases were misdiagnosed as @entity7 and 2 were misdiagnosed as @entity6 . The mean follow-up duration of this series was 38.8 months (range, 3-142 months). Twenty-two @entity0 had died, 12 were still alive, and 2 were lost to follow-up. The median survival time of the 36 @entity0 was 29.0 months (95% confidence interval = 20.0-38.0), and the 1-, 2-, 3-, and 5-year overall survival rates were 80.6%, 57.1%, 34.4%, and 25.8%, respectively. The 5-year survival rate of 25.8% was lower than 5-year absolute survival rate of 39.2% for @entity7 @entity0 who had undergone surgical resection during the same period at our center. For @entity0 who underwent a radical operation, the 5-year survival rate of 32.0% for @entity8 @entity0 was also lower than that of 41.7% (908/2175) for @entity7 @entity0 . In univariate analysis, pN (pN0/pN1-3) (p = 0.003) and operation type (radical/palliative) (p = 0.006) significantly influenced the median survival time of @entity8 @entity0 . In multivariate analysis, pN (pN0/pN1-3) (p = 0.002) and operation type (radical/palliative) (p = 0.004) were independent prognostic factors. CONCLUSIONS: Primary esophageal @entity8 is a @entity5 and prone to be misdiagnosed. Lymph node @entity1 and operation are independent prognostic factors. Surgical resection is the primary treatment, but the prognosis is poor.

title: Primary XXXX of the esophagus.

answer: @entity8


abstract: The purpose of this work is to extract three-dimensional (3D) motion trajectories of internal implanted and external skin-attached markers from kV cone-beam projections and reduce image artifact from @entity0 motion in cone-beam computed tomography (CBCT) from on-board imager. Cone beam radiographic projections were acquired for a mobile phantom and liver @entity0 with internal implanted and external skin-attached markers. An algorithm was developed to automatically find the positions of the markers in the projections. It uses normalized cross-correlation between a template image of a metal seed marker and the projections to find the marker position. From these positions and time-tagged angular views, the marker 3D motion trajectory was obtained over a time interval of nearly one minute, which is the time required for scanning. This marker trajectory was used to remap the pixels of the projections to eliminate motion. Then, the motion-corrected projections were used to reconstruct CBCT. An algorithm was developed to extract 3D motion trajectories of internal and external markers from cone-beam projections using a kV monoscopic on-board imager. This algorithm was tested and validated using a mobile phantom and @entity0 with liver masses that had radio-markers implanted in the @entity1 and attached to the skin. The extracted motion trajectories were used to investigate motion correlation between internal and external markers in liver @entity0 . Image artifacts from respiratory motion were reduced in CBCT reconstructed from cone-beam projections that were preprocessed to remove motion shifts obtained from marker tracking. With this method, motion-related image artifacts such as blurring and @entity2 were reduced, and contrast and position resolutions were improved significantly in CBCT reconstructed from motion-corrected projections. Furthermore, correlated internal and external marker 3D-motion tracks obtained from the kV projections might be useful for 4DCBCT, beam gating and @entity1 motion monitoring or tracking.

title: An algorithm to extract three-dimensional motion by marker tracking in the kV projections from an on-board imager: four-dimensional cone-beam CT and XXXX tracking implications.

answer: @entity1


abstract: BACKGROUND: Endomyocardial biopsy (EMB) is the gold standard method for the diagnosis of cellular rejection (CR) after @entity1 ( @entity1 ). OBJECTIVE: To test the hypothesis that tissue Doppler imaging (TDI) could detect @entity2 and add diagnostic information compared to conventional Doppler. METHODS: Fifty-four @entity1 @entity0 underwent 129 EMB and a TDI echocardiographic study within 24 hours. We compared @entity1 @entity0 with @entity2 versus @entity1 @entity0 with CR < 3A, with a normal matched control group (13 @entity0 ). We measured TDI systolic (S), early diastolic (e'), late diastolic (a') velocities and e'/a' ratio in the left ventricular annulus, basal and medium (mid) segments of the septal (SEP), lateral (LAT), inferior (INF), anterior (ANT) walls; and in the right ventricular annulus. RESULTS: @entity1 @entity0 showed @entity2 in 39/129 (30.2%) EMB. The best isolated predictor for CR diagnosis was a'LAT, with a sensitivity of 76.3%, specificity of 73.8% (p = 0.001). In the multivariate analysis, a'LAT (p = 0.001), a'SEP (p = 0.002), e'/a' LAT ratio (p = 0.006), e'Mitral/ e'LAT ratio (p = 0.014), SINF (p = 0.009) predicted @entity2 . We obtained a score with a sensitivity of 88.2%, accuracy of 79.6% and negative predictive value of 92.9% to diagnose @entity2 . Conventional Doppler (mitral and pulmonary venous flow) was not relevant to predict @entity2 . CONCLUSION: TDI added diagnostic information to predict @entity2 compared to conventional Doppler. A TDI-based model could become a potential method to detect @entity2 after @entity1 .

title: Tissue doppler echocardiography in the diagnosis of XXXX rejection.

answer: @entity1


abstract: OBJECTIVE: To investigate the correlation between perceived performance in prioritized activities and physical conditions related to grip reconstruction. DESIGN: Retrospective clinical outcome study. @entity0 : Forty-seven individuals with @entity2 were included in the study. Each @entity0 underwent tendon transfer surgery in the hand between November 2002 and April 2009 and had a complete 1-year follow-up. METHODS: Functional characteristics and performance data were collected from our database and medical records. @entity0 ' perceived performances in prioritized activities were recorded using the Canadian Occupational Performance Measurement. Preoperative data included age at surgery, time since injury, severity of @entity1 and hand dominance. At 1-year follow-up, grip strength, key pinch strength, finger pulp-to-palm distance, distance between thumb and index finger and wrist flexion were measured. Correlation rank coefficient was used to test the possible relationship between physical data and activity performance. RESULTS: There were improvements in both functional factors and in rated performance of prioritized activities after surgery. There was no correlation between performance change and any of the physical functions, the factors known before surgery, or the functional outcome factors. CONCLUSION: No correlation exists between a single functional outcome parameter and the @entity0 ' perceived performance of their prioritized goals in reconstructive hand surgery in @entity2 .

title: Performance of prioritized activities is not correlated with functional factors after grip reconstruction in XXXX .

answer: @entity2


abstract: @entity5 is endemic in over 70 countries, in which more than 200 million @entity0 are infected with the various schistosome species. Understanding the physiological processes underlying key developmental events could be useful in developing novel chemotherapeutic reagents or infection intervention strategies. Calmodulin is a small, @entity3 -sensing protein found in all eukaryotes and, although the protein has been previously identified in various @entity1 stages and implicated in egg hatching and miracidia transformation, few molecular and functional data are available for this essential protein. Herein, we report the molecular cloning, expression, and functional characterization of calmodulin in the miracidia and primary sporocyst stages of @entity2 . Two transcripts, SmCaM1 and SmCaM2, were cloned and sequenced, and a recombinant SmCaM1 protein was expressed in @entity4 and used to generate anti-CaM antibodies. The 2 protein sequences were highly conserved when compared to other model organisms. The alignment of the predicted proteins of both SmCaM1 and SmCaM2 exhibited 99% identity to each other and 97-98% identity with @entity0 calmodulins. Analysis of steady-state transcript abundance indicate that the 2 calmodulin transcripts differ in their stage-associated expression patterns, although the CaM protein isotype appears to be constitutively expressed during early larval development. Application of RNAi to larval parasites results in a "stunted growth" phenotype in sporocysts with 30 and 35% reduction in transcript abundance for SmCaM1 and SmCaM2, respectively, and a corresponding 35% reduction in protein level after incubation in double-stranded RNA. Differential expression of CaM transcripts during early larval development and a growth defect-inducing effect associated with partial transcript and protein inhibition as a result of RNAi suggest a potentially important role of calmodulin during early larval development.

title: Cloning and functional characterization of two calmodulin genes during larval development in the parasitic flatworm XXXX .

answer: @entity1


abstract: A retrospective analysis is reported in 232 @entity0 with clinical Stage I @entity3 diagnosed between 1980 and 1988, treated with combined surgery and adjuvant irradiation. @entity2 were restaged according to the FIGO (1988) surgical staging system (SSS) in order to assess the prognostic value of this revised classification and of the conventional clinico-pathological features (age, performance status, grade and depth of @entity1 ). The 5-year relapse-free survival (RFS) and @entity4 ( @entity4 ) of the series was 85% and 90.8%, respectively. Both 5-year RFS and @entity4 were not significantly different adopting the FIGO (1971) clinical Stage (Stage IA 93% and 88% vs Stage IB 88.5 and 82%. respectively) whereas they were significant by FIGO SSS (Stage IA 96% and 93% vs Stage IB 94% and 88.5% vs Stage IC 74% and 63%, respectively) (p=0.001 and p=0.0005, respectively). Other factors that significantly affected 5-year RFS or @entity4 at univariate analysis were age (p=0.01 and p<0.0001, respectively), performance status (p=0.035 and p=0.001, respectively), grade (p=0.015 and p<0.0001, respectively) and @entity1 (p=0.0017 and p=0.0003, respectively). A multivariate analysis of these prognostic variables showed that FIGO SSS was the only significant and independent (p=0.01) indicator for recurrence. However, when therapy was added to the model, FIGO SSS failed to retain significance (p=0.11). Concerning @entity4 age (p<0.0001), performance status (p=0.04) and FIGO SSS (p=0.05) were significant and independent prognosticators, also when therapy was included in the analysis. In conclusion, this study shows that the new FIGO SSS is a useful prognosticator as well as is age and performance status, in early Stage @entity3 .

title: Multivariate-analysis of prognostic factors in 232 @entity0 with clinical stage-I XXXX using the new figo surgical staging system.

answer: @entity3


abstract: A retrospective analysis is reported in 232 @entity0 with clinical Stage I @entity3 diagnosed between 1980 and 1988, treated with combined surgery and adjuvant irradiation. @entity2 were restaged according to the FIGO (1988) surgical staging system (SSS) in order to assess the prognostic value of this revised classification and of the conventional clinico-pathological features (age, performance status, grade and depth of @entity1 ). The 5-year relapse-free survival (RFS) and @entity4 ( @entity4 ) of the series was 85% and 90.8%, respectively. Both 5-year RFS and @entity4 were not significantly different adopting the FIGO (1971) clinical Stage (Stage IA 93% and 88% vs Stage IB 88.5 and 82%. respectively) whereas they were significant by FIGO SSS (Stage IA 96% and 93% vs Stage IB 94% and 88.5% vs Stage IC 74% and 63%, respectively) (p=0.001 and p=0.0005, respectively). Other factors that significantly affected 5-year RFS or @entity4 at univariate analysis were age (p=0.01 and p<0.0001, respectively), performance status (p=0.035 and p=0.001, respectively), grade (p=0.015 and p<0.0001, respectively) and @entity1 (p=0.0017 and p=0.0003, respectively). A multivariate analysis of these prognostic variables showed that FIGO SSS was the only significant and independent (p=0.01) indicator for recurrence. However, when therapy was added to the model, FIGO SSS failed to retain significance (p=0.11). Concerning @entity4 age (p<0.0001), performance status (p=0.04) and FIGO SSS (p=0.05) were significant and independent prognosticators, also when therapy was included in the analysis. In conclusion, this study shows that the new FIGO SSS is a useful prognosticator as well as is age and performance status, in early Stage @entity3 .

title: Multivariate-analysis of prognostic factors in 232 XXXX with clinical stage-I @entity3 using the new figo surgical staging system.

answer: @entity0


abstract: In this study, synchronous spontaneous, independent liver and @entity0 were detected in a Bearded dragon ( @entity6 ). The @entity0 consisted of @entity4 as well as in situ @entity2 and two @entity3 . The biliary epithelial cells and the @entity1 showed @entity5 -immunoreactivity for claudin-7. The gallbladder epithelial cells, its @entity3 and @entity2 showed basolateral cross-reactivity for claudin-7. We think that the humanised anti-claudin-7 antibody is a good marker for the detection of different primary cholangiocellular and @entity0 in Bearded dragons. The cholangiocytes, the @entity1 , the endothelial cells of the liver and the epithelial cells and @entity0 all showed claudin-5 cross-reactivity. The humanised anti-cytokeratin AE1-AE3 antibody showed cross-reactivity in the biliary epithelial cells, @entity1 cells, epithelial cells and @entity0 cells of the gallbladder. It seems that this humanised antibody is a useful epithelial marker for the different neoplastic lesions of epithelial cells in reptiles. The humanised anti-a-smooth muscle actin (a-SMA) antibody showed intense cross-reactivity in the smooth muscle cells of the hepatic vessels and in the muscle layer of the gallbladder. The portal myofibroblasts, the endothelial cells of the sinusoids and the stromal cells of the @entity1 and @entity0 were positive for a-SMA. The antibovine anti-vimentin and humanised anti-Ki-67 antibodies did not show crossreactivity in the different samples from the Bearded dragon.

title: Claudin-7-positive synchronous spontaneous @entity4 , @entity2 and XXXX in a Bearded dragon ( @entity6 ).

answer: @entity3


abstract: In this study, synchronous spontaneous, independent liver and @entity0 were detected in a Bearded dragon ( @entity6 ). The @entity0 consisted of @entity4 as well as in situ @entity2 and two @entity3 . The biliary epithelial cells and the @entity1 showed @entity5 -immunoreactivity for claudin-7. The gallbladder epithelial cells, its @entity3 and @entity2 showed basolateral cross-reactivity for claudin-7. We think that the humanised anti-claudin-7 antibody is a good marker for the detection of different primary cholangiocellular and @entity0 in Bearded dragons. The cholangiocytes, the @entity1 , the endothelial cells of the liver and the epithelial cells and @entity0 all showed claudin-5 cross-reactivity. The humanised anti-cytokeratin AE1-AE3 antibody showed cross-reactivity in the biliary epithelial cells, @entity1 cells, epithelial cells and @entity0 cells of the gallbladder. It seems that this humanised antibody is a useful epithelial marker for the different neoplastic lesions of epithelial cells in reptiles. The humanised anti-a-smooth muscle actin (a-SMA) antibody showed intense cross-reactivity in the smooth muscle cells of the hepatic vessels and in the muscle layer of the gallbladder. The portal myofibroblasts, the endothelial cells of the sinusoids and the stromal cells of the @entity1 and @entity0 were positive for a-SMA. The antibovine anti-vimentin and humanised anti-Ki-67 antibodies did not show crossreactivity in the different samples from the Bearded dragon.

title: Claudin-7-positive synchronous spontaneous XXXX , @entity2 and @entity3 in a Bearded dragon ( @entity6 ).

answer: @entity4


abstract: In this study, synchronous spontaneous, independent liver and @entity0 were detected in a Bearded dragon ( @entity6 ). The @entity0 consisted of @entity4 as well as in situ @entity2 and two @entity3 . The biliary epithelial cells and the @entity1 showed @entity5 -immunoreactivity for claudin-7. The gallbladder epithelial cells, its @entity3 and @entity2 showed basolateral cross-reactivity for claudin-7. We think that the humanised anti-claudin-7 antibody is a good marker for the detection of different primary cholangiocellular and @entity0 in Bearded dragons. The cholangiocytes, the @entity1 , the endothelial cells of the liver and the epithelial cells and @entity0 all showed claudin-5 cross-reactivity. The humanised anti-cytokeratin AE1-AE3 antibody showed cross-reactivity in the biliary epithelial cells, @entity1 cells, epithelial cells and @entity0 cells of the gallbladder. It seems that this humanised antibody is a useful epithelial marker for the different neoplastic lesions of epithelial cells in reptiles. The humanised anti-a-smooth muscle actin (a-SMA) antibody showed intense cross-reactivity in the smooth muscle cells of the hepatic vessels and in the muscle layer of the gallbladder. The portal myofibroblasts, the endothelial cells of the sinusoids and the stromal cells of the @entity1 and @entity0 were positive for a-SMA. The antibovine anti-vimentin and humanised anti-Ki-67 antibodies did not show crossreactivity in the different samples from the Bearded dragon.

title: Claudin-7-positive synchronous spontaneous @entity4 , @entity2 and @entity3 in a Bearded dragon ( XXXX ).

answer: @entity6


abstract: In this study, synchronous spontaneous, independent liver and @entity0 were detected in a Bearded dragon ( @entity6 ). The @entity0 consisted of @entity4 as well as in situ @entity2 and two @entity3 . The biliary epithelial cells and the @entity1 showed @entity5 -immunoreactivity for claudin-7. The gallbladder epithelial cells, its @entity3 and @entity2 showed basolateral cross-reactivity for claudin-7. We think that the humanised anti-claudin-7 antibody is a good marker for the detection of different primary cholangiocellular and @entity0 in Bearded dragons. The cholangiocytes, the @entity1 , the endothelial cells of the liver and the epithelial cells and @entity0 all showed claudin-5 cross-reactivity. The humanised anti-cytokeratin AE1-AE3 antibody showed cross-reactivity in the biliary epithelial cells, @entity1 cells, epithelial cells and @entity0 cells of the gallbladder. It seems that this humanised antibody is a useful epithelial marker for the different neoplastic lesions of epithelial cells in reptiles. The humanised anti-a-smooth muscle actin (a-SMA) antibody showed intense cross-reactivity in the smooth muscle cells of the hepatic vessels and in the muscle layer of the gallbladder. The portal myofibroblasts, the endothelial cells of the sinusoids and the stromal cells of the @entity1 and @entity0 were positive for a-SMA. The antibovine anti-vimentin and humanised anti-Ki-67 antibodies did not show crossreactivity in the different samples from the Bearded dragon.

title: Claudin-7-positive synchronous spontaneous @entity4 , XXXX and @entity3 in a Bearded dragon ( @entity6 ).

answer: @entity2


abstract: To reduce @entity4 , @entity6 , @entity9 and @entity8 @entity3 , the @entity1 and @entity7 Group B conducted a phase 2 trial of @entity4 , @entity9 , and @entity2 for newly diagnosed, nonbulky stages I and II @entity5 . Ninety-nine assessable @entity0 received 6 cycles of @entity4 25 mg/m(2), @entity9 6 mg/m(2), and @entity2 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 @entity0 (72.7%) and partial remission in 24 of 99 @entity0 (24.2%). The CR rate was 81% when using PET criteria. Two @entity0 have died of @entity5 progression. Median follow-up for nonprogressing @entity0 is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for @entity0 with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive @entity0 was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive @entity0 (P = .0001). Although the CR rate and PFS were lower than anticipated, @entity0 with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.

title: @entity4 , @entity9 , and @entity2 (CALGB 50203) for stage I/II nonbulky XXXX : pretreatment prognostic factors and interim PET.

answer: @entity5


abstract: To reduce @entity4 , @entity6 , @entity9 and @entity8 @entity3 , the @entity1 and @entity7 Group B conducted a phase 2 trial of @entity4 , @entity9 , and @entity2 for newly diagnosed, nonbulky stages I and II @entity5 . Ninety-nine assessable @entity0 received 6 cycles of @entity4 25 mg/m(2), @entity9 6 mg/m(2), and @entity2 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 @entity0 (72.7%) and partial remission in 24 of 99 @entity0 (24.2%). The CR rate was 81% when using PET criteria. Two @entity0 have died of @entity5 progression. Median follow-up for nonprogressing @entity0 is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for @entity0 with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive @entity0 was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive @entity0 (P = .0001). Although the CR rate and PFS were lower than anticipated, @entity0 with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.

title: XXXX , @entity9 , and @entity2 (CALGB 50203) for stage I/II nonbulky @entity5 : pretreatment prognostic factors and interim PET.

answer: @entity4


abstract: To reduce @entity4 , @entity6 , @entity9 and @entity8 @entity3 , the @entity1 and @entity7 Group B conducted a phase 2 trial of @entity4 , @entity9 , and @entity2 for newly diagnosed, nonbulky stages I and II @entity5 . Ninety-nine assessable @entity0 received 6 cycles of @entity4 25 mg/m(2), @entity9 6 mg/m(2), and @entity2 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 @entity0 (72.7%) and partial remission in 24 of 99 @entity0 (24.2%). The CR rate was 81% when using PET criteria. Two @entity0 have died of @entity5 progression. Median follow-up for nonprogressing @entity0 is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for @entity0 with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive @entity0 was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive @entity0 (P = .0001). Although the CR rate and PFS were lower than anticipated, @entity0 with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.

title: @entity4 , XXXX , and @entity2 (CALGB 50203) for stage I/II nonbulky @entity5 : pretreatment prognostic factors and interim PET.

answer: @entity9


abstract: To reduce @entity4 , @entity6 , @entity9 and @entity8 @entity3 , the @entity1 and @entity7 Group B conducted a phase 2 trial of @entity4 , @entity9 , and @entity2 for newly diagnosed, nonbulky stages I and II @entity5 . Ninety-nine assessable @entity0 received 6 cycles of @entity4 25 mg/m(2), @entity9 6 mg/m(2), and @entity2 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 @entity0 (72.7%) and partial remission in 24 of 99 @entity0 (24.2%). The CR rate was 81% when using PET criteria. Two @entity0 have died of @entity5 progression. Median follow-up for nonprogressing @entity0 is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for @entity0 with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive @entity0 was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive @entity0 (P = .0001). Although the CR rate and PFS were lower than anticipated, @entity0 with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.

title: @entity4 , @entity9 , and XXXX (CALGB 50203) for stage I/II nonbulky @entity5 : pretreatment prognostic factors and interim PET.

answer: @entity2


abstract: MicroRNAs (miRNAs) are non-coding RNAs that play important roles in post-transcriptional regulation. Identification of miRNAs is crucial to understanding their biological mechanism. Recently, machine-learning approaches have been employed to predict miRNA precursors (pre-miRNAs). However, features used are divergent and consequently induce different performance. Thus, feature selection is critical for pre-miRNA prediction. We generated an optimized feature subset including 13 features using a hybrid of genetic algorithm and support vector machine (GA-SVM). Based on SVM, the classification performance of the optimized feature subset is much higher than that of the two feature sets used in microPred and miPred by five-fold cross-validation. Finally, we constructed the classifier @entity1 -SF to predict the most recently identified @entity0 pre-miRNAs in miRBase (version 16). Compared with microPred and miPred, @entity1 -SF achieved much higher classification performance. Accuracies were 93.97%, 86.21% and 64.66% for @entity1 -SF, microPred and miPred, respectively. Thus, @entity1 -SF is effective for identifying pre-miRNAs.

title: Predicting XXXX microRNA precursors based on an optimized feature subset generated by GA-SVM.

answer: @entity0


abstract: Individuals with @entity2 following @entity3 often show biased performance on landmark bisection tasks (judging if a single item is transected at its midpoint) and search tasks (where they seek target(s) from an array of items). Interestingly, it appears that bisection deficits dissociate from other measures of neglect (including search tasks), and neglect @entity0 with bisection deficits typically have more posterior injury than those without these symptoms. While previous studies in healthy adults have examined each of these tasks independently, our aim was to directly contrast brain activity between these two tasks. Our design used displays that were interpreted as landmark bisection stimuli in some blocks of trials and as search arrays on other trials. Therefore, we used a design where low-level perceptual and motor responses were identical across tasks. Both tasks generated significant activity in bilateral midfusiform gyrus, largely right lateralized activity in the posterior parietal cortex, left lateralized activity in the left motor cortex (consistent with right handed response) and generally right lateralized insular activation. Several brain areas showed task-selective activations when the two tasks were directly compared. Specifically, the superior parietal cortex was selectively activated during the landmark task. On the other hand, the search task caused stronger bilateral activation in the anterior insula, along with midfusiform gyrus, medial superior frontal areas, thalamus and right putamen. This work demonstrates that healthy adults show an anatomical dissociation for @entity1 and bisection behavior similar to that reported in neurological @entity0 , and provides coordinates for future brain stimulation studies.

title: Distinct anatomy for XXXX and bisection: a neuroimaging study.

answer: @entity1


abstract: BACKGROUND: There are still no definite treatments for refractory @entity4 ( @entity4 ). In this pilot study, we evaluated the use of @entity1 (CyA) treatment in @entity0 with refractory @entity4 . METHODS: We prospectively collected clinical data of CyA treatment (4-8 mg/kg/d, oral administration) for refractory @entity4 @entity0 using the same protocol among several hospitals. @entity4 is defined as the persistence or recurrence of @entity2 (37.5  C or more of an axillary temperature) at the end of the second intravenous immunoglobulin (2 g/kg) following the initial one. RESULTS: Subjects were enrolled out of 329 @entity4 @entity0 who were admitted to our 8 hospitals between January 2008 and June 2010. Among a total of 28 @entity0 of refractory @entity4 treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased @entity6 levels, the other 4 became afebrile within 4 to 5 days. However, 6 @entity0 (21.4%) failed to become afebrile within 5 days after the start of CyA and/or high @entity2 returned after becoming afebrile within 5 days. Although @entity7 developed in 9 @entity0 at 3 to 7 days after the start of CyA treatment, there were no serious adverse effects such as @entity5 . Four @entity0 (1.2%), 2 before and the other 2 after the start of CyA treatment, developed @entity3 . CONCLUSION: CyA treatment is considered safe and well tolerated, and a promising option for @entity0 with refractory @entity4 . Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.

title: XXXX treatment for @entity4 refractory to initial and additional intravenous immunoglobulin.

answer: @entity1


abstract: BACKGROUND: There are still no definite treatments for refractory @entity4 ( @entity4 ). In this pilot study, we evaluated the use of @entity1 (CyA) treatment in @entity0 with refractory @entity4 . METHODS: We prospectively collected clinical data of CyA treatment (4-8 mg/kg/d, oral administration) for refractory @entity4 @entity0 using the same protocol among several hospitals. @entity4 is defined as the persistence or recurrence of @entity2 (37.5  C or more of an axillary temperature) at the end of the second intravenous immunoglobulin (2 g/kg) following the initial one. RESULTS: Subjects were enrolled out of 329 @entity4 @entity0 who were admitted to our 8 hospitals between January 2008 and June 2010. Among a total of 28 @entity0 of refractory @entity4 treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased @entity6 levels, the other 4 became afebrile within 4 to 5 days. However, 6 @entity0 (21.4%) failed to become afebrile within 5 days after the start of CyA and/or high @entity2 returned after becoming afebrile within 5 days. Although @entity7 developed in 9 @entity0 at 3 to 7 days after the start of CyA treatment, there were no serious adverse effects such as @entity5 . Four @entity0 (1.2%), 2 before and the other 2 after the start of CyA treatment, developed @entity3 . CONCLUSION: CyA treatment is considered safe and well tolerated, and a promising option for @entity0 with refractory @entity4 . Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.

title: @entity1 treatment for XXXX refractory to initial and additional intravenous immunoglobulin.

answer: @entity4


abstract: The effects of magnetic stimulation on @entity5 -induced migration of white matter astrocytes were studied using an established animal model. @entity9 was injected into the dorsal spinal cord funiculus of adult @entity0 on the left side at T10-11. Animals then received 1.52 Tesla-pulsed magnetic stimulation for 5 min at different frequencies (0-20 Hz) for 14 consecutive days. Selected animals received the non-competitive @entity12 inhibitor @entity10 (10 microM), prior to stimulation at 10 Hz. Lesion volumes were measured in @entity6 / @entity7 -stained sections. Expression of @entity1 ( @entity1 ), @entity11 ( @entity11 ) and extra-cellular signal-regulated kinasel/2 ( @entity8 ) near the @entity3 was examined by Western blotting with quantification using an image analysis system. Lesion volumes decreased and @entity1 and p- @entity8 expression increased with increasing magnetic stimulation frequency (0-10 Hz). @entity11 expression was not affected at any frequency. Pretreatment with @entity10 reduced @entity1 and @entity8 expression and increased lesion volumes in response to stimulation at 10 Hz. It is concluded that magnetic stimulation increases the migration of astrocytes to @entity4 . Activation of the @entity8 signaling pathway is proposed to mediate astrocyte migration and @entity2 formation in response to @entity5 .

title: @entity5 -induced astrocyte migration and XXXX formation: effects of magnetic stimulation frequency.

answer: @entity2


abstract: The effects of magnetic stimulation on @entity5 -induced migration of white matter astrocytes were studied using an established animal model. @entity9 was injected into the dorsal spinal cord funiculus of adult @entity0 on the left side at T10-11. Animals then received 1.52 Tesla-pulsed magnetic stimulation for 5 min at different frequencies (0-20 Hz) for 14 consecutive days. Selected animals received the non-competitive @entity12 inhibitor @entity10 (10 microM), prior to stimulation at 10 Hz. Lesion volumes were measured in @entity6 / @entity7 -stained sections. Expression of @entity1 ( @entity1 ), @entity11 ( @entity11 ) and extra-cellular signal-regulated kinasel/2 ( @entity8 ) near the @entity3 was examined by Western blotting with quantification using an image analysis system. Lesion volumes decreased and @entity1 and p- @entity8 expression increased with increasing magnetic stimulation frequency (0-10 Hz). @entity11 expression was not affected at any frequency. Pretreatment with @entity10 reduced @entity1 and @entity8 expression and increased lesion volumes in response to stimulation at 10 Hz. It is concluded that magnetic stimulation increases the migration of astrocytes to @entity4 . Activation of the @entity8 signaling pathway is proposed to mediate astrocyte migration and @entity2 formation in response to @entity5 .

title: XXXX -induced astrocyte migration and @entity2 formation: effects of magnetic stimulation frequency.

answer: @entity5


abstract: A phase II trial was performed to evaluate the efficacy and @entity2 of a double modulation of @entity6 ( @entity6 ) by @entity7 ( @entity8 ) and @entity9 (LV) as first line chemotherapy in advanced @entity1 . Between January 1990, and April 1992, 42 @entity0 with metastatic or advanced recurrent (inoperable) @entity1 were entered into the study. Therapy consisted of a sequential combination of @entity8 , LV and @entity6 . @entity8 was administered at a dose of 150 mg/m2 over 20 minutes I.V. infusion at hour (h) 0, followed 19 h later by LV 50 mg/m2 over 2 h infusion. @entity6 900 mg/m2 was given by I.V. push injection at h 20. Starting 24 h after @entity8 administration all @entity0 received LV 15 mg/m2 intramuscularly every 6 h for six doses. Treatment was repeated every 15 days until progressive disease, severe @entity2 , or @entity3 . Four @entity0 were considered not evaluable for response. Objective regression (OR) was observed in 14 of 38 @entity0 (37%, 95% confidence interval 23-53%). Two @entity0 (5%) obtained complete response (CR) and 12 (32%) partial response (PR). Median time to treatment failure was 6 months (range 1-21). Median survival for the whole group of @entity0 was 13 months (range 1-27). @entity2 was within acceptable limits but one therapy-related @entity3 due to severe @entity5 and @entity4 was observed. Double modulation of @entity6 with @entity8 and low dose of LV is an active regimen against advanced @entity1 and represents a promising strategy that should be further explored.

title: Double-modulation of @entity6 by XXXX and @entity9 in advanced @entity1 .

answer: @entity7


abstract: A phase II trial was performed to evaluate the efficacy and @entity2 of a double modulation of @entity6 ( @entity6 ) by @entity7 ( @entity8 ) and @entity9 (LV) as first line chemotherapy in advanced @entity1 . Between January 1990, and April 1992, 42 @entity0 with metastatic or advanced recurrent (inoperable) @entity1 were entered into the study. Therapy consisted of a sequential combination of @entity8 , LV and @entity6 . @entity8 was administered at a dose of 150 mg/m2 over 20 minutes I.V. infusion at hour (h) 0, followed 19 h later by LV 50 mg/m2 over 2 h infusion. @entity6 900 mg/m2 was given by I.V. push injection at h 20. Starting 24 h after @entity8 administration all @entity0 received LV 15 mg/m2 intramuscularly every 6 h for six doses. Treatment was repeated every 15 days until progressive disease, severe @entity2 , or @entity3 . Four @entity0 were considered not evaluable for response. Objective regression (OR) was observed in 14 of 38 @entity0 (37%, 95% confidence interval 23-53%). Two @entity0 (5%) obtained complete response (CR) and 12 (32%) partial response (PR). Median time to treatment failure was 6 months (range 1-21). Median survival for the whole group of @entity0 was 13 months (range 1-27). @entity2 was within acceptable limits but one therapy-related @entity3 due to severe @entity5 and @entity4 was observed. Double modulation of @entity6 with @entity8 and low dose of LV is an active regimen against advanced @entity1 and represents a promising strategy that should be further explored.

title: Double-modulation of @entity6 by @entity7 and XXXX in advanced @entity1 .

answer: @entity9


abstract: A phase II trial was performed to evaluate the efficacy and @entity2 of a double modulation of @entity6 ( @entity6 ) by @entity7 ( @entity8 ) and @entity9 (LV) as first line chemotherapy in advanced @entity1 . Between January 1990, and April 1992, 42 @entity0 with metastatic or advanced recurrent (inoperable) @entity1 were entered into the study. Therapy consisted of a sequential combination of @entity8 , LV and @entity6 . @entity8 was administered at a dose of 150 mg/m2 over 20 minutes I.V. infusion at hour (h) 0, followed 19 h later by LV 50 mg/m2 over 2 h infusion. @entity6 900 mg/m2 was given by I.V. push injection at h 20. Starting 24 h after @entity8 administration all @entity0 received LV 15 mg/m2 intramuscularly every 6 h for six doses. Treatment was repeated every 15 days until progressive disease, severe @entity2 , or @entity3 . Four @entity0 were considered not evaluable for response. Objective regression (OR) was observed in 14 of 38 @entity0 (37%, 95% confidence interval 23-53%). Two @entity0 (5%) obtained complete response (CR) and 12 (32%) partial response (PR). Median time to treatment failure was 6 months (range 1-21). Median survival for the whole group of @entity0 was 13 months (range 1-27). @entity2 was within acceptable limits but one therapy-related @entity3 due to severe @entity5 and @entity4 was observed. Double modulation of @entity6 with @entity8 and low dose of LV is an active regimen against advanced @entity1 and represents a promising strategy that should be further explored.

title: Double-modulation of @entity6 by @entity7 and @entity9 in advanced XXXX .

answer: @entity1


abstract: A phase II trial was performed to evaluate the efficacy and @entity2 of a double modulation of @entity6 ( @entity6 ) by @entity7 ( @entity8 ) and @entity9 (LV) as first line chemotherapy in advanced @entity1 . Between January 1990, and April 1992, 42 @entity0 with metastatic or advanced recurrent (inoperable) @entity1 were entered into the study. Therapy consisted of a sequential combination of @entity8 , LV and @entity6 . @entity8 was administered at a dose of 150 mg/m2 over 20 minutes I.V. infusion at hour (h) 0, followed 19 h later by LV 50 mg/m2 over 2 h infusion. @entity6 900 mg/m2 was given by I.V. push injection at h 20. Starting 24 h after @entity8 administration all @entity0 received LV 15 mg/m2 intramuscularly every 6 h for six doses. Treatment was repeated every 15 days until progressive disease, severe @entity2 , or @entity3 . Four @entity0 were considered not evaluable for response. Objective regression (OR) was observed in 14 of 38 @entity0 (37%, 95% confidence interval 23-53%). Two @entity0 (5%) obtained complete response (CR) and 12 (32%) partial response (PR). Median time to treatment failure was 6 months (range 1-21). Median survival for the whole group of @entity0 was 13 months (range 1-27). @entity2 was within acceptable limits but one therapy-related @entity3 due to severe @entity5 and @entity4 was observed. Double modulation of @entity6 with @entity8 and low dose of LV is an active regimen against advanced @entity1 and represents a promising strategy that should be further explored.

title: Double-modulation of XXXX by @entity7 and @entity9 in advanced @entity1 .

answer: @entity6


abstract: Age is the most accepted prognostic factor in @entity2 . Other parameters, such as @entity1 size, grading, extrathyroidal extension, have also been associated with the prognosis of these @entity1 . Since the identification of reliable prognostic factors is essential to avoid unnecessary aggressive treatment for a disease, such as @entity2 , which only rarely is fatal, we studied two indices of cell proliferation in @entity0 with @entity2 , in relation to their outcome. We studied two groups of @entity0 with @entity2 , selected in a way to have one group (33 @entity0 ) with a good outcome and one (16 @entity0 ) with a fatal outcome, after a follow-up of at least 5 years. By immunohistochemistry the @entity1 of all @entity0 were analyzed for the expression of the @entity3 ( @entity3 )/ @entity3 . In 38 (77.5%) of them also the nuclear DNA content and the percentages of S-phases were analyzed by flow cytometric analysis. At diagnosis the two groups of @entity0 differed significantly with regard to age and extrathyroidal extension, but not for @entity1 size and grading. A significant difference (p=0.02) was found in the positivity of @entity3 / @entity3 expression between the fatal outcome group (66.6%) and the surviving @entity0 (27%), and in the percentage of cells in the S-phase, 16.4+/-7.7% in the fatal outcome group @entity0 and 6.0+/-2.6% in the surviving @entity0 (p=0.0001). No difference was found in the nuclear DNA content of the two groups. A positive correlation was found between @entity3 expression and S-phase (r(s)=0.55; p<0.001). A positive correlation was found between age and both the percentage of S-phase cells (r(s)=0.48; p<0.002) and @entity3 expression (r(s)=0.36; p<0.009). In a multivariate analysis (Cox model) age and S-phase had independent prognostic significance (regression coefficient: 3.85 and 1.70, respectively), while @entity3 was not an independent variable (0.98). Our results indicate that differentiated @entity2 with fatal outcome are characterized by two parameters of active cell proliferation (S-phase cell fraction and @entity3 expression), which can be used as useful prognostic factors.

title: Markers of cell-proliferation as prognostic factors in differentiated XXXX .

answer: @entity2